Andrew Johns Source Confirmed

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

Researcher

University of Central Arkansas

faculty

12 h-index 74 pubs 525 cited

Is this your profile? Verify and claim your profile

Biography and Research Information

OverviewAI-generated summary

Andrew Johns investigates the use and toxicity of immune checkpoint inhibitors (ICIs) in cancer patients. His recent publications focus on outcomes related to bone metastases, skeletal-related events, and survival in patients with non-small cell lung cancer treated with ICIs. Johns has also published on the role of serum albumin as an early prognostic marker for ICI monotherapy benefit, and on the toxicity and survival impact of ICIs among older adults with advanced cancer. His work includes examining the incidence and risk factors for ICI-related thrombocytopenia and hepatitis injury, as well as comparing manual chart review with claims data for evaluating ICI-related adverse events. Johns' research network includes collaborators from the University of Arkansas for Medical Sciences, with whom he has co-authored multiple publications.

Metrics

  • h-index: 12
  • Publications: 74
  • Citations: 525

Selected Publications

  • Efficient Self-Driving: A Study on the Behavioral Cloning based Autonomous Navigation (2025) DOI

Collaborators

Researchers in the database who share publications

Similar Researchers

Based on overlapping research topics